(E)-3-[3-(3-methylbutoxy)phenyl]prop-2-enoic acid | 1260378-24-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-3-[3-(3-methylbutoxy)phenyl]prop-2-enoic acid
• CAS: 1260378-24-2
• 化学式: C₁₄H₁₈O₃
• mdl: MFCD11200605
• 分子量: 234.295
• InChiKey: AJBZDCJDHXEGBS-VOTSOKGWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.357
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-3-[3-(3-methylbutoxy)phenyl]prop-2-enoic acid 、 (S)-methyl 7-amino-8-oxo-8-(quinolin-8-ylamino)octanoate trifluoroacetate 在 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 、 苯 为溶剂， 反应 48.0h， 以71%的产率得到(S,E)-methyl 7-(3-(3-(isopentyloxy)phenyl)acrylamido)-8-oxo-8-(quinolin-8-ylamino)octanoate
  参考文献：
  名称：

  Antimalarial histone deacetylase inhibitors containing cinnamate or NSAID components

  摘要：

  Malaria is the most lethal parasite-mediated tropical infectious disease, killing 1-2 million people each year. An emerging drug target is the enzyme Plasmodium falciparum histone deacetylase 1 (PfHDAC1). We report 26 compounds designed to bind the zinc and exterior surface around the entrance to the active site of PfHDAC1, 16 displaying potent in vitro antimalarial activity (IC(50) < 100 nM) against P. falciparum. Selected compounds were shown to cause hyperacetylation of P. falciparum histones and be > 10-fold more cytotoxic towards P. falciparum than a normal human cell type (NFF). Twenty-two inhibitors feature cinnamic acid derivatives or non-steroidal anti-inflammatory drugs (NSAIDs) as HDAC-binding components. A homology model of PfHDAC1 enzyme gives new insights to interactions likely made by some of these inhibitors. Results support PfHDAC1 as a promising new antimalarial drug target. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.09.096

文献信息

• Antimalarial histone deacetylase inhibitors containing cinnamate or NSAID components
  作者：Nicole C. Wheatley、Katherine T. Andrews、Truc L. Tran、Andrew J. Lucke、Robert C. Reid、David P. Fairlie

  DOI：10.1016/j.bmcl.2010.09.096

  日期：2010.12

  Malaria is the most lethal parasite-mediated tropical infectious disease, killing 1-2 million people each year. An emerging drug target is the enzyme Plasmodium falciparum histone deacetylase 1 (PfHDAC1). We report 26 compounds designed to bind the zinc and exterior surface around the entrance to the active site of PfHDAC1, 16 displaying potent in vitro antimalarial activity (IC(50) < 100 nM) against P. falciparum. Selected compounds were shown to cause hyperacetylation of P. falciparum histones and be > 10-fold more cytotoxic towards P. falciparum than a normal human cell type (NFF). Twenty-two inhibitors feature cinnamic acid derivatives or non-steroidal anti-inflammatory drugs (NSAIDs) as HDAC-binding components. A homology model of PfHDAC1 enzyme gives new insights to interactions likely made by some of these inhibitors. Results support PfHDAC1 as a promising new antimalarial drug target. (C) 2010 Elsevier Ltd. All rights reserved.